T1	Participants 90 110	rheumatoid arthritis
T2	Participants 201 226	rheumatoid arthritis (RA)
T3	Participants 473 490	28 joints (DAS28)
T4	Participants 545 658	patients with RA in whom disease had remained active despite treatment with disease-modifying antirheumatic drugs
